You’ve got questions—we’ve got answers
Are you new to PANZYGA? Or undergoing treatment and looking for PANZYGA resources or support? Explore the most commonly asked questions below for more information, including links to additional details and helpful tools.
PANZYGA is a liquid medicine for infusion that contains immunoglobulin G (IgG) and is called intravenous immunoglobulin (IVIg) therapy. It is made from human plasma, which is carefully selected from the blood of healthy donors using strict FDA guidelines to ensure safety.
PANZYGA is FDA-approved to treat chronic inflammatory demyelinating polyneuropathy (CIDP), primary immunodeficiency (PI) in patients 2 years of age and older, and chronic immune thrombocytopenia (cITP)—all conditions in which immunoglobulin therapy has proven to be an effective treatment.
PANZYGA offers two co-pay programs for eligible patients, as well as support navigating your financial assistance options through Pfizer IGuideTM. The Drug Co-Pay Program may help eligible, commercially insured patients pay as little as $0 for PANZYGA, while the Admin Support Co-Pay Program may help eligible patients receive up to $1,500 per calendar year for costs associated with administering therapy—including home infusions, administration services, and supplies/equipment. Additional terms and conditions apply.*
In a clinical trial of adult patients with CIDP who received PANZYGA, the majority of patients improved†:
- 80% of the 69 patients treated with 1 g/kg of PANZYGA
- 92% of the 36 patients treated with 2 g/kg of PANZYGA
†Results were based on improved patient scores in an adjusted INCAT exam that measured the ability to use arms and legs.
In a clinical trial of patients aged 2 years or older with PI, PANZYGA helped prevent serious bacterial infections (SBIs):
- 51 patients received PANZYGA at a dose between 200 mg/kg and 800 mg/kg of body weight every 3 or 4 weeks
- 50 patient-years were studied and 4 SBIs were observed, which is equal to 0.08 SBIs per patient per year‡
‡Serious bacterial infections (SBIs) included pneumonia, bacteremia or sepsis, osteomyelitis/septic arthritis, visceral abscesses, or bacterial meningitis.
In a clinical trial of adult patients with cITP, PANZYGA helped increase platelets (a type of blood cell) and decrease bleeding:
- 36 patients received PANZYGA at a dose of 2 g/kg of body weight administered as 2 daily 1 g/kg doses given on 2 consecutive days
- Approximately 81% (29 of 36) of patients responded to PANZYGA with an increase in platelet count within 7 days of treatment
- For adults with CIDP, more than 5% of patients experienced headache (15%), fever (14%), skin irritation (10%), and increased blood pressure (8%)
- For people 2 years of age and older with PI, more than 5% of patients experienced headache (22%), stomach pain (upper) (14%), fever (14%), nausea (10%), sinus infection (8%), fatigue (6%), and bronchitis (6%)
- For adults with cITP, more than 5% of patients experienced headache (50%), fever (23%), nausea (18%), vomiting (10%), dizziness (10%), and anemia (10%)
PANZYGA is given by IV infusion through a needle inserted into your vein. This may be done at home, at an infusion center, or in a hospital, but it is always done by a healthcare professional. Your infusion will start at a slow rate, while your healthcare provider monitors you for signs of infusion reactions. If you tolerate it well, they may gradually increase your infusion rate.
Infusion reactions can include headache, abdominal pain, fever, nausea, fatigue, vomiting, dizziness, skin irritation, increased blood pressure, sinus infection, bronchitis, and anemia. They may slow or stop your infusion depending on your infusion reaction.
Your first PANZYGA infusion will take the most time. After your initial infusion, the time it takes for your daily infusions will vary by patient, but these are some examples for adults:
between 1 ½ to 2 ½ hours per day§
between 1 ¼ to 1 ½ hours per day§
about 3 hours per day§
§The CIDP example is based on an 80 g or 160 g total dose for a 176-lb (80-kg) patient and an infusion administration ramp-up rate of 1, 2, 4, 8, and 12 mg/kg/min. The PI example is based on a 30 g or 40 g total dose for a 176-lb (80-kg) patient and an infusion administration ramp-up rate of 1, 4, 8, and 14 mg/kg/min. The cITP example is based on a 160 g total dose for a 176-lb (80-kg) patient and an infusion administration ramp-up rate of 1, 4, and 8 mg/kg/min.
It is important to record the details of each PANZYGA infusion so that your healthcare provider can monitor your progress, which is why Pfizer provides an infusion tracker. Be sure to fill out every section of your infusion tracker and keep an accurate record of each time your PANZYGA is administered. During your first few infusions, it is recommended that you ask your infusion nurse or trainer to help you complete your tracker.
You can download and print the PANZYGA Therapy Tracker or download the Ig Companion mobile app to your phone for your convenience.
*Eligible, commercially insured patients may receive a maximum benefit of $12,500 per year or the cost of a patient’s co-pay in a 12-month period (whichever is less) for claims received by the program. The value of the admin co-pay support is limited to a maximum of $1,500 for PANZYGA per calendar year or the cost of patient co-pay in a 12-month period (whichever is less) for claims received by the program. No membership fees are required. Federal and state healthcare beneficiaries are not eligible. The PANZYGA Co-Pay Program is good only in the US and Puerto Rico. The PANZYGA Admin Support Co-Pay Program is not valid for Massachusetts or Rhode Island residents. Terms and conditions/eligibility requirements apply. See full Terms and Conditions on the Financial assistance programs page.
